Atenolol Treatment for Infantile Haemangioma

Abstract

Since 2008, propranolol has become the first line recommended treatment for infantile haemangiomas (IH) ^1,2. Propranolol is a synthetic beta-adrenergic receptor-blocking agent that is non-selective because it blocks both beta 1 and beta 2 adrenergic receptors ^3,4. The most commonly reported side effects in infants treated with propranolol for IH are sleep disturbance, cool mottled peripheries and bronchial hyperactivity ^3,5 and concerns have been raised about the potential long-term neurodevelopmental or cognitive effects^{6, 7}. A proportion of patients has to stop treatment because of adverse effects, thus treatments with other beta-blockers are considered.

This article is protected by copyright. All rights reserved.

http://ift.tt/2jTGZkN